GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » EV-to-Revenue

Ocumension Therapeutics (HKSE:01477) EV-to-Revenue : 13.82 (As of May. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ocumension Therapeutics's enterprise value is HK$3,723.9 Mil. Ocumension Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$269.5 Mil. Therefore, Ocumension Therapeutics's EV-to-Revenue for today is 13.82.

The historical rank and industry rank for Ocumension Therapeutics's EV-to-Revenue or its related term are showing as below:

HKSE:01477' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.82   Med: 53.1   Max: 433.39
Current: 13.82

During the past 6 years, the highest EV-to-Revenue of Ocumension Therapeutics was 433.39. The lowest was 7.82. And the median was 53.10.

HKSE:01477's EV-to-Revenue is ranked worse than
61.97% of 1036 companies
in the Biotechnology industry
Industry Median: 7.96 vs HKSE:01477: 13.82

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Ocumension Therapeutics's stock price is HK$6.98. Ocumension Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42. Therefore, Ocumension Therapeutics's PS Ratio for today is 16.82.


Ocumension Therapeutics EV-to-Revenue Historical Data

The historical data trend for Ocumension Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics EV-to-Revenue Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - 867.63 138.48 30.14 13.43

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 138.48 - 30.14 - 13.43

Competitive Comparison of Ocumension Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Ocumension Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's EV-to-Revenue falls into.



Ocumension Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ocumension Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3723.858/269.472
=13.82

Ocumension Therapeutics's current Enterprise Value is HK$3,723.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$269.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (HKSE:01477) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ocumension Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.98/0.415
=16.82

Ocumension Therapeutics's share price for today is HK$6.98.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines